SecBot SecBot
SECBOTREPLAY Home › Report › SRXH

SRXH · SRX Global Inc

SRX Global Inc. · 8-K filed Sep 2, 2026 at 16:47 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Sep 2, 2026 at 16:47 ET

SRX Global Inc. (SRXH) entered into a secured debt financing transaction with CERo Therapeutics Holdings, Inc. (CERO), acquiring a Consolidated Senior Secured Promissory Note consolidating $5.67M in prior notes and providing up to $6M in additional advances, for a maximum aggregate loan amount of $11.67M. The loan is secured by a first-priority security interest in all of CERO's assets, including its intellectual property and clinical-stage CER-1236 T-cell therapy program, as well as a pledge of 100% of the subsidiary's stock and an unconditional guaranty from the subsidiary. This is a debt investment by SRXH, not an acquisition, and represents a moderate deployment of capital into a high-risk, pre-revenue biotech company with a near-term maturity date of October 15, 2026, which can be extended by SRXH for up to four 30-day periods at its discretion.

  • SRX Global acquired a senior secured promissory note from CERo Therapeutics Holdings with an aggregate maximum loan amount of $11,666,108.77.
  • The note consolidates $5,666,108.77 in prior notes and provides for up to $6,000,000 in additional advances, with an initial advance of $775,665.00 funded on August 27, 2026.
  • The loan matures on October 15, 2026, but SRXH can extend the maturity date for up to four consecutive 30-day periods at its discretion.
  • The loan is secured by a first-priority security interest in substantially all assets of CERo Therapeutics, Inc., including key patents and the CER-1236 T-cell therapy program, plus a pledge of 100% of the subsidiary's stock and an unconditional guaranty.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access